NFE2L2 and esophageal squamous cell carcinoma: Although it is widely believed that ESCC cells can hijack the NRF2 pathway as a survival mechanism—and that NRF2 inhibitors may offer a therapeutic benefit in ESCC cases with elevated NRF2 activity—rigorous, context-specific studies are still needed to validate this approach in preclinical and clinical settings.